Imunon (IMNN) Competitors $1.09 -0.05 (-4.39%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.11 +0.02 (+1.83%) As of 03/28/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. AADI, PDSB, CTMX, OKYO, OTLK, ALVR, ITRM, RPTX, IBIO, and IMMXShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Aadi Bioscience (AADI), PDS Biotechnology (PDSB), CytomX Therapeutics (CTMX), OKYO Pharma (OKYO), Outlook Therapeutics (OTLK), AlloVir (ALVR), Iterum Therapeutics (ITRM), Repare Therapeutics (RPTX), iBio (IBIO), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Aadi Bioscience PDS Biotechnology CytomX Therapeutics OKYO Pharma Outlook Therapeutics AlloVir Iterum Therapeutics Repare Therapeutics iBio Immix Biopharma Imunon (NASDAQ:IMNN) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Which has higher valuation and earnings, IMNN or AADI? Imunon has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K31.87-$19.51M-$1.60-0.68Aadi Bioscience$25.07M1.88-$65.76M-$2.35-0.81 Do institutionals and insiders hold more shares of IMNN or AADI? 4.5% of Imunon shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in IMNN or AADI? Imunon received 12 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 100.00% of users gave Imunon an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes23100.00% Underperform VotesNo VotesAadi BioscienceOutperform Votes1139.29% Underperform Votes1760.71% Which has more risk & volatility, IMNN or AADI? Imunon has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Does the media favor IMNN or AADI? In the previous week, Imunon had 7 more articles in the media than Aadi Bioscience. MarketBeat recorded 9 mentions for Imunon and 2 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 1.52 beat Imunon's score of 0.06 indicating that Aadi Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aadi Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer IMNN or AADI? Imunon currently has a consensus target price of $21.50, suggesting a potential upside of 1,872.48%. Aadi Bioscience has a consensus target price of $1.67, suggesting a potential downside of 12.74%. Given Imunon's stronger consensus rating and higher probable upside, equities research analysts clearly believe Imunon is more favorable than Aadi Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Aadi Bioscience 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is IMNN or AADI more profitable? Imunon has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -230.05% -128.98% Aadi Bioscience -246.06%-71.87%-57.28% SummaryImunon beats Aadi Bioscience on 13 of the 19 factors compared between the two stocks. Remove Ads Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.94M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.587.2623.6018.74Price / Sales31.87218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.776.386.894.23Net Income-$19.51M$142.34M$3.20B$247.47M7 Day Performance14.74%-5.15%-3.06%-2.29%1 Month Performance22.38%-7.55%1.52%-5.81%1 Year Performance-33.54%-11.06%9.37%-0.96% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.2289 of 5 stars$1.09-4.4%$21.50+1,872.5%-33.5%$15.94M$500,000.00-0.5830AADIAadi Bioscience1.272 of 5 stars$2.10+6.1%$1.67-20.6%-18.4%$51.86M$25.07M-0.9240Positive NewsPDSBPDS Biotechnology1.8406 of 5 stars$1.34+8.9%$11.67+770.6%-68.2%$51.18MN/A-1.1620Earnings ReportShort Interest ↓Gap UpCTMXCytomX Therapeutics4.2976 of 5 stars$0.63-2.6%$5.02+693.6%-71.2%$50.70M$138.10M3.72170Short Interest ↑Gap DownOKYOOKYO Pharma3.2125 of 5 stars$1.49-1.2%$7.00+369.8%-9.4%$50.42MN/A0.007Short Interest ↓Positive NewsGap UpOTLKOutlook Therapeutics1.5484 of 5 stars$1.54-1.9%$10.20+562.3%-88.9%$49.31MN/A-0.2120ALVRAlloVir2.1858 of 5 stars$9.66+0.1%N/A-50.5%$48.72MN/A-0.48110Gap UpITRMIterum Therapeutics2.077 of 5 stars$1.40+1.4%$5.00+257.1%-18.2%$48.41MN/A-1.0710Positive NewsRPTXRepare Therapeutics3.3921 of 5 stars$1.14+3.2%$4.50+296.5%-77.7%$48.25M$53.48M-0.57180Positive NewsIBIOiBio0.5635 of 5 stars$4.86-4.3%$4.30-11.5%+1.5%$47.99M$375,000.000.00100Positive NewsGap UpIMMXImmix Biopharma2.7311 of 5 stars$1.73+4.8%$7.00+304.6%-44.6%$47.59MN/A-2.049Earnings ReportPositive News Remove Ads Related Companies and Tools Related Companies AADI Competitors PDSB Competitors CTMX Competitors OKYO Competitors OTLK Competitors ALVR Competitors ITRM Competitors RPTX Competitors IBIO Competitors IMMX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMNN Stock Free IMNN Stock Alerts